FEZ family zinc finger 2Genealiases: FEZ · FEZL · FKSG36 · TOF · ZFP312 · ZNF312
Q-omics provides the consensus-scored FEZF2 profile across patient tissues and cancer cell-line models. FEZF2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FEZF2 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, FEZF2 RNA expression shows 10,710 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight BLCA, BRCA, and READ as cancer lineages where FEZF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FEZF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FEZF2 survival associations across molecular data types. FEZF2 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FEZF2 RNA expression–survival associations across cancer types. High FEZF2 expression shows unfavorable associations in BLCA, CESC, SARC, KIRC and OV, but favorable associations in LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify BLCA as the clearest survival context for FEZF2 RNA expression.
This table summarizes FEZF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FEZF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FEZF2 shows lower tumor expression in BRCA and higher tumor expression in COAD, PRAD, UCEC and LUAD. The BRCA box plot shows higher FEZF2 RNA expression in normal versus tumor tissue (log2 FC = −0.364, t-test p < 0.001).
This table shows molecular features associated with FEZF2 in patient tissues and cancer cell lines. In patient samples, FEZF2 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, FEZF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
